Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease

Journal of Hepatology

Volumn 60, Issue 1, 2014, Pages 167-174

  Cusi, Kenneth ^a,b,e,f   Chang, Zhi ^a   Harrison, Steve ^d   Lomonaco, Romina ^a   Bril, Fernando ^a   Orsak, Beverly ^a   Ortiz Lopez, Carolina ^a   Hecht, Joan ^a,e   Feldstein, Ariel E ^f,g   Webb, Amy ^b,e   Louden, Christopher ^b   Goros, Martin ^b   Tio, Fermin ^c,e  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c Mays Cancer Center at UT Health San Antonio   (United States)

^d BROOKE ARMY MEDICAL CENTER   (United States)

^e SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

^g UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Cytokeratin 18; Diabetes; Fatty liver; Insulin resistance; NAFLD; NASH

Indexed keywords

CYTOKERATIN 18;

ADIPOSE TISSUE; ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; DIAGNOSTIC VALUE; FAT CONTENT; FATTY LIVER; FEMALE; HEPATITIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFLAMMATION; INSULIN RESISTANCE; LIVER; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MUSCLE TISSUE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OBESITY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SCREENING TEST; SENSITIVITY AND SPECIFICITY;

CYTOKERATIN-18; DIABETES; FATTY LIVER; INSULIN RESISTANCE; NAFLD; NASH;

BIOLOGICAL MARKERS; FATTY LIVER; FEMALE; HUMANS; INSULIN RESISTANCE; KERATIN-18; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS;

EID: 84890547086     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2013.07.042     Document Type: Article

References (33)

1. D.M. Torres, C.D. Williams, and S.A. Harrison Features, diagnosis, and treatment of non-alcoholic fatty liver disease Clin Gastroenterol Hepatol 10 2012 837 858
2. K. Cusi Role of obesity and lipotoxicity in the development of non-alcoholic steatohepatitis: pathophysiology and clinical implications Gastroenterology 142 2012 711 725
3. N. Chalasani, Z. Younossi, J.E. Lavine, A.M. Diehl, E.M. Brunt, and K. Cusi The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association Hepatology 55 2012 2005 2023
4. C. Ortiz-Lopez, R. Lomonaco, B. Orsak, J. Finch, Z. Chang, and V.G. Kochunov Prevalence of prediabetes and diabetes and metabolic profile of patients with non-alcoholic fatty liver disease (NAFLD) Diabetes Care 35 2012 873 878
5. C.D. Williams, J. Stengel, M.I. Asike, D.M. Torres, J. Shaw, and M. Contreras Prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study Gastroenterology 140 2011 124 131
6. J.D. Browning, L.S. Szczepaniak, R. Dobbins, P. Nuremberg, J.D. Horton, and J.C. Cohen Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity Hepatology 40 2004 1387 1395
7. S. Harrison, D. Oliver, H. Arnold, S. Gogia, and B. Neuschwander-Tetri Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease Gut 57 2008 1441 1447
8. G. Musso, R. Gambino, M. Cassader, and G. Pagano Meta-analysis: Natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity Ann Med 43 2011 617 649
9. L.A. Adams, and A.E. Feldstein Non-invasive diagnosis of non-alcoholic fatty liver and non-alcoholic steatohepatitis J Dig Dis 12 2011 10 16
10. S. Zelber-Sagi, V. Ratziu, I. Zvibel, I. Goldiner, L. Blendis, and G. Morali The association between adipocytokines and biomarkers for non-alcoholic fatty liver disease-induced liver injury: a study in the general population Eur J Gastroenterol Hepatol 24 2012 262 269
11. A. Baranova, P. Lal, A. Birerdinc, and Z.M. Younossi Non-invasive markers for hepatic fibrosis BMC Gastroenterol 11 2011 91
12. M.H. Miller, M.A. Ferguson, and J.F. Dillon Systematic review of performance of non-invasive biomarkers in the evaluation of non-alcoholic fatty liver disease Liver Int 31 2011 461 473
13. A.E. Feldstein, A. Wieckowska, A.R. Lopez, Y.C. Liu, N.N. Zein, and A.J. McCullough Cytokeratin-18 fragment levels as noninvasive biomarkers for non-alcoholic steatohepatitis: a multicenter validation study Hepatology 50 2009 1072 1078
14. Y. Yilmaz, A.E. Kedrah, and O. Ozdogan Cytokeratin-18 fragments and biomarkers of the metabolic syndrome in non-alcoholic steatohepatitis World J Gastroenterol 15 2009 4387 4391
15. J. Shen, H.L. Chan, G.L. Wong, P.C. Choi, A.W. Chan, and H.Y. Chan Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum biomarkers J Hepatol 56 2012 1363 1370
16. R. Belfort, S.A. Harrison, K. Brown, C. Darland, J. Finch, and J. Hardies A placebo-controlled trial of pioglitazone in subjects with non-alcoholic steatohepatitis N Engl J Med 355 2006 2297 2307
17. R. Lomonaco, C. Ortiz-Lopez, B. Orsak, J. Finch, A. Webb, and F. Bril Role of ethnicity in overweight and obese patients with non-alcoholic steatohepatitis Hepatology 54 2011 837 845
18. R. Lomonaco, C. Ortiz-Lopez, B. Orsak, A. Webb, J. Hardies, and C. Darland Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with non-alcoholic fatty liver disease Hepatology 55 2012 1389 1397
19. K. Cusi, A. Consoli, and R. DeFronzo Metabolic effects of metformin on glucose and lactate metabolism in NIDDM J Clin Endo Metab 81 1996 4059 4067
20. K. Cusi, K. Maezono, A. Osman, M. Pendergrass, M. Patti, and T. Pranawatapatr Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle J Clin Invest 105 2000 311 320
21. R. Belfort, R. Berria, J. Cornell, and K. Cusi Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome J Clin Endocrinol Metab 95 2010 829 836
22. D.E. Kleiner, E.M. Brunt, M. Van Natta, C. Behling, M.J. Contos, and O.W. Cummings Design and validation of a histological scoring system for non-alcoholic fatty liver disease Hepatology 41 2005 1313 1321
23. S.R. Mehta, E.L. Thomas, J.D. Bell, D.G. Johnston, and S.D. Taylor-Robinson Non-invasive means of measuring hepatic fat content World J Gastroenterol 14 2008 3476 3483
24. D.L. Diab, L. Yerian, P. Schauer, S.R. Kashyap, R. Lopez, and S.L. Hazen Cytokeratin 18 fragment levels as a noninvasive biomarker for non-alcoholic steatohepatitis in bariatric surgery patients Clin Gastroenterol Hepatol 6 2008 1249 1254
25. Z.M. Younossi, M. Jarrar, C. Nugent, M. Randhawa, M. Afendy, and M. Stepanova A novel diagnostic biomarker panel for obesity-related non-alcoholic steatohepatitis (NASH) Obes Surg 18 2008 1430 1437
26. S. Francque, A. Verrijken, I. Mertens, G. Hubens, E.V. Marck, and P. Pelckmans Non-invasive assessment of non-alcoholic fatty liver disease in obese or overweight patients Clin Gastroenterol Hepatol 10 2012 1162 1168
27. D. Joka, K. Wahl, S. Moeller, J. Schlue, B. Vaske, and M.J. Bahr Prospective biopsy-controlled evaluation of cell death biomarkers for prediction of liver fibrosis and non-alcoholic steatohepatitis Hepatology 55 2012 455 464
28. E. Koehler, J. Swain, S. Sanderson, A. Krishnan, K. Watt, and M. Charlton Growth hormone, dehydroepiandrosterone and adiponectin levels in non-alcoholic steatohepatitis: an endocrine signature for advanced fibrosis in obese patients Liver Int 32 2012 279 286
29. A. Gastaldelli, K. Cusi, M. Pettiti, J. Hardies, Y. Miyazaki, and R. Berria Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects Gastroenterology 133 2007 496 506
30. A. Gastaldelli, S. Harrison, R. Belfort-Aguiar, J. Hardies, B. Balas, and S. Schenker Pioglitazone in the treatment of NASH: the role of adiponectin Aliment Pharmacol Ther 32 2010 769 775
31. T.I. Tamimi, H.M. Elgouhari, N. Alkhouri, L.M. Yerian, M.P. Berk, and R. Lopez An apoptosis panel for non-alcoholic steatohepatitis diagnosis J Hepatol 54 2011 1224 1229
32. C.O. Zein, R. Lopez, X. Fu, J.P. Kirwan, L.M. Yerian, and A.J. McCullough Pentoxifylline decreases oxidized lipid products in non-alcoholic steatohepatitis: new evidence on the potential therapeutic mechanism Hepatology 56 2012 1291 1299
33. A.E. Feldstein, R. Lopez, T.A. Tamimi, L. Yerian, Y.M. Chung, and M. Berk Mass spectrometric profiling of oxidized lipid products in human non-alcoholic fatty liver disease and non-alcoholic steatohepatitis J Lipid Res 51 2010 3046 3054